Difications of EVs, to be able to generate a potent DDS. Solutions: We proved ablility to produce, isolate (differential ultracentrifugation) and characterize (dynamic light scattering, nanoparticle tracking analysis (NTA), protein dosage, western blot, proteomics, cryoTEM) EVs from murine MSC with yields coherent with their use in this project. Importantly, we developed a freeze-drying protocol for their long-term storage, with no effect on vesicle numbers, structure (cryoTEM) and content material (proteomic). Right after labelling having a lypophilic dye, EVs were incubated with the parent cells or foreign cells (NIH3T3), within the presence of endocytosis inhibitors, and tracked by flow cytometry. All experiments have been also performed on liposomal industrial standards (PC/Chol) as a comparison. Results: EVs were 94 11 nm (NTA, n = 9) with a production yield of 3.41 protein and 9.48.108 particles/106 cells (n = 9). The western blot and proteomics evaluation evidenced the presence of EV-specific markers which include TSG101, CD81 and ADAM10. The EVs were internalized to a greater extent than their liposomal counterparts in each target cells (n = three). Our preliminary data suggest that they could follow distinctive endocytic routes. Among the processes evaluated for drug loading, EVs have been extruded by means of 50 nm membranes with no damage. We’re presently investigating whether the performed modifications effect their internalization rate and pathway. Summary/conclusion: Our team has been able to reproducibly isolate, characterize and label mMSC-derived EVs. The EVs show increased internalization in vitro when compared with DPP-2 Inhibitor MedChemExpress liposomes at the moment employed as DDS,Thursday, 03 Maywhatever the target cell sort, and EVs may well adhere to a unique endocytic route than liposomes. We propose here to present our most current results concerning the rationale of using EVs as vectors for drug delivery. Funding: The PhD project is funded by MESR (Minist e de l’Enseignement Sup ieur et de la Recherche) funding.PT07.A systematic review and meta-analysis of parameters affecting the therapeutic prospective of mesenchymal stem cell-derived extracellular vesicles in pre-clinical studies Faezeh Shekari1; Sara Assar Kashani2; Abdo Reza Nazari2; Ensiyeh Haji Zadeh2; Hossein Baharvand1 Department of Stem Cells and Developmental Biology, Cell Science Analysis Center, Royan Institute for Stem Cell Biology and Technology, Tehran, Iran, Tehran, Iran; 2Royan institute, Tehran, IranBackground: Mesenchymal stem cells (MSC) therapy is among the most normally employed cellular therapy in human clinical trials. Considering that MSCs secrete extracellular vesicles (EVs) to mediate in regeneration, EVs are undergoing comprehensive evaluation as a replacement or adjutant to cells in cellular therapy in pre-clinical studies. To date, there has been no meta-analysis of studies employing MSC-EV therapy in animal research. Procedures: By searching systematically in PubMed and Scopus databases, greater than 1000 reports had been identified. Immediately after screening for eligibility, a total of roughly one hundred research are found to report MSC-EV therapy in animal illness models. Outcomes: All of the discovered pre-clinical studies reporting the therapeutic possible of MSC-derived EVs underwent comprehensive review, quality assessment and information IRAK4 Inhibitor review extraction. Most of these research employed animal models for kidney, heart, skin and lung disease also as cancer. Though culture conditions with the EV-producing cells have overlapping characteristics, we discussed lots of diverse technical aspects,.